Evaluation of tuberculosis transmission in Tehran: using RFLP and spoligotyping methods

The Journal of Infection
Parissa FarniaAli Akbar Velayati

Abstract

To evaluate the DNA polymorphism among Mycobacterium tuberculosis (MTB) strains isolated from new smear positive tuberculosis (TB) patients residing in Tehran capital city of Iran, during the year 2001. IS6110-restriction fragment length polymorphism (RFLP) and spoligotyping analyses were performed on 129 M. tuberculosis strains. Additional patient's information was collected for further epidemiological analyses. Patients whose isolates had identical RFLP and spoligotyping patterns were considered a cluster. The results show that the IS6110 were polymorphic and the strains with 8 or 9 IS6110 copy number were more frequently defected (42%). Out of 129 available isolates, 56 (43%) belonged to clusters and 72 (57%) did not. The risk factors like age, sex, family history or close contact and intravenous drug abuse were associated with clustering. Whereas, unemployment (61%) and poor living conditions (83%) contributed to diseases development in both groups. Spoligotyping of M. tuberculosis strains resulted in 46 different patterns, out of which 38 patterns were unique and reported for the first time. We found one M. tuberculosis strains with a pattern characteristic of the Beijing family. In the studied time period both reactivatio...Continue Reading

References

Feb 1, 1991·The American Review of Respiratory Disease·C M NolanD R Risser
Dec 1, 1995·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·S DasP R Narayanan
Jan 1, 1997·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·N FomukongM D Cave
Aug 7, 1999·The Journal of Infectious Diseases·D van SoolingenJ D van Embden
Jul 2, 2002·American Journal of Respiratory and Critical Care Medicine·Stephen E WeisPeter F Barnes

❮ Previous
Next ❯

Citations

May 18, 2006·Emerging Infectious Diseases·UNKNOWN European Concerted Action on New Generation Genetic Markers and Techniques for the Epidemiology and Control of Tuberculosis
Feb 15, 2014·BioMed Research International·Tomasz JagielskiJacek Bielecki
Jun 27, 2006·Scandinavian Journal of Infectious Diseases·Ali Akbar VelayatiMohammad Reza Masjedi
Nov 2, 2016·Jundishapur Journal of Microbiology·Mahya PourostadiMohammad Asgharzadeh
Sep 1, 2016·BMC Infectious Diseases·Sophia B GeorghiouTimothy C Rodwell
Mar 1, 2014·International Journal of Mycobacteriology·Rashid Ramazanzadeh, Kourosh Sayhemiri
Sep 1, 2014·International Journal of Mycobacteriology·Mohanad Mohsin AhmedNalin Rastogi
Jun 9, 2021·BMC Public Health·Behzad KianiAlireza Mohammadi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.